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Abstract
A continuing problem in the area of oligonucleotide-based therapeutics is the poor access of these
molecules to their sites of action in the nucleus or cytosol. A number of approaches to this
problem have emerged. One of the most interesting is the use of ligand-oligonucleotide conjugates
to promote receptor mediated cell uptake and delivery. Here we provide an overview of recent
developments regarding targeted conjugates, including use of peptides, carbohydrates and small
molecules as ligands. Additionally we discuss our own experience with this approach and point
out both advantages and limitations.
INTRODUCTION
The last decade has seen a surge of interest in the therapeutic utilization of various types of
oligonucleotides including siRNA, miRNA, single strand antisense oligonucleotides (ASOs)
and splice switching oligonucleotides (SSOs) 1-5. While a number of molecules have entered
clinical trials, a persistent problem in this field is the poor delivery of oligonucleotides to
their sites of pharmacological action in the cytosol or nucleus of tissue cells. Rapid clearance
from the circulation, enzymatic degradation, inability to be taken up efficiently by cells, and
trapping within endosomes all constrain the pharmacological effectiveness of the different
types of oligonucleotides to various degrees 6-9.
Chemical modification has been an important approach to improving the pharmacology of
oligonucleotides, providing increased potency, specificity and reduced side effects 10,11.
One form of chemical modification, the attachment of ligands designed to improve delivery,
has attracted considerable attention recently. Linkage of peptide, lipid, carbohydrate or small
molecule moieties at the 5’ or 3’ positions of oligonucleotides has been done either to
provide selective binding to cell surface receptors or to alter the physical properties of the
oligonucleotide so as to change its clearance kinetics and biodistribution. The ligand
conjugation strategy partially contrasts with another major approach to delivery of
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oligonucleotides, namely the use of nanoparticle carriers 12-14. While nanocarriers can also
include targeting ligands, their vastly greater size as compared to molecular scale conjugates
implies a far more restricted biodistribution 15. Additionally there are often toxicity issues
associated with the cationic lipid or polymer components that are usually included in
nanoparticles 16. Thus ligand-oligonucleotide conjugates provide an important alternative to
nanocarriers as a delivery strategy.
Several excellent reviews have described many of the issues involved in the conjugation of
various ligands with oligonucleotides 11,17-20. One important aspect is the relative merits of
solid phase versus solution phase conjugation. Solid phase synthesis is highly efficient and
facilitates purification, but the availability of appropriate synthons is often a limitation.
Another concern is the need for both ligand and oligonucleotide to be stable under the
conditions of synthesis. By contrast, solution phase conjugation first pursues synthesis of
each component under the most appropriate and efficient conditions. However, the
conjugation reaction itself may be inefficient; further, substantial post-synthesis purification
problems can occur. Various groups have utilized both strategies for conjugation, but with
the majority preferring solution phase approaches. Recently, some interesting new
chemistries have been brought to bear on oligonucleotide conjugation including use of ‘click
chemistry’ 21,22 and novel phosphoramidation reactions 23.
Much work has been done on the conjugation of various lipids to siRNA or other
oligonucleotides; this can be done at either 3’ or 5’ positions using a variety of
linkages 24,25. Lipid conjugation can provide substantial advantages in terms of the blood
clearance kinetics, biodistribution and tissue uptake of the oligonucleotide. This was
demonstrated early on with cholesterol conjugation of siRNA that causes the molecule to
bind to lipoproteins, thus increasing circulation time and promoting uptake into the liver via
lipoprotein receptors 26,27. Similar approaches have been undertaken with tocopherol 28 and
with a variety of fatty acids and other lipid moieties 29
There has also been extensive work on peptide-oligonucleotide conjugates. For example, a
number of laboratories have coupled so-called ‘cell penetrating peptides’ 30-32 to SSOs,
particularly to uncharged morpholino or peptide nucleic acid oligomers. These have proven
to be promising in correction of defects involved in Duchenne muscular dystrophy and have
shown good effects both in muscle cell culture and in dystrophic mice 33-35. Other groups
have conjugated siRNAs, ASOs or SSOs with peptides designed to bind to specific
receptors. Our laboratory has worked extensively on such targeted conjugates (see below) as
have others 36. A variety of linkages have been used to conjugate peptides and
oligonucleotides including amide, thioether, thiol-maleimide, ester, and disulfide. An
important question is whether use of a bioreversible linkage such as a disulfide is needed to
attain biological activity. This does not seem to be the case, however, and both bioreversible
and nonreversible linkages can work well, at least for monovalent conjugates 37-39.
Conjugation of carbohydrate moieties to oligonucleotides can provide targeting to the lectin-
like proteins that exist on many cell types. Conjugation of monosaccharides to an
oligonucleotide can be approached in a simple manner through the preparation of
carbohydrate containing phosphoramidites. However, it is far more challenging to prepare
oligonucleotides bearing the more complex oligosaccharide structures needed for optimal
lectin recognition 18. Recently, ‘click chemistry’ has been used to synthesize complicated
oligonucleotide glycoconjugates including branched structures 40,41. An exciting recent
application of this approach involves delivery of glycoconjugates of siRNA to liver via the
asialoglycoprotein receptor, a cell surface lectin found on hepatocytes 42.
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A lesser amount of work has been done on conjugates of small molecules to
oligonucleotides. This is somewhat surprising given the plethora of high affinity, receptor-
specific ligands for that are known or discoverable 43. While the number of potential small
molecule ligands is not unlimited 44, it nonetheless provides a rich field for discovery of
oligonucleotide targeting agents. Our laboratory has synthesized and tested mono- and
multi-valent conjugates of SSOs with anisamide, a small molecule ligand for the sigma
receptor 45. Other groups have synthesized and characterized conjugates with folate 46 or
with anandamide 47 that bind respectively to the folate receptor (FOLR1) or a cannabinoid
receptor. In all of these cases significant biological activity was seen in the absence of any
transfection agent.
Thus, over the last few years a substantial body of work has appeared regarding the
chemistry and biology of oligonucleotide conjugates. In the sections below we will focus on
our own experience with these types of molecules and deal with both their potential utility
and with possible liabilities.
PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
Our laboratory has worked extensively on peptide conjugates of SSOs and siRNA. The
ligands chosen were peptides that are known to have high affinities for particular cell
surface receptors that tend to be over-expressed in certain tumor cells. For example, we have
extensively used mono- and multi-valent versions of the cyclic RGD peptide that binds
selectively to the αvβ3 integrin that is over-expressed in angiogenic vasculature and in
certain tumors 48. We have also used bombesin-like peptides that bind to BB2, a G Protein
Coupled Receptor over-expressed in certain carcinomas 49. The paragraphs below describe
the synthesis of these conjugates.
Solid Phase Synthesis of a Splice Switching Oligonucleotide for Conjugation
The solid phase synthesis of a 2’-O-Me phosphorothioate anionic antisense oligonucleotide
with splice switching capability, a 3’ fluorophore, and a 5’ linker for ligand attachment
follows our published procedures 39. The sequence we usually employed is termed SSO 623
(5’-GTT ATT CTT TAG AAT GGT GC-3’). The synthesis used a AB3400 DNA
synthesizer and was conventional with the exceptions noted below. The synthesis started on
solid supports having 2’ -OMe C or Tamra fluorophore at the 3’-end. Detritylation was done
using 3% trichloroacetic acid in dichloromethane for 90 seconds followed by an acetonitrile
wash. Base condensation was done by adding 0.25M solution of 5-ethylthio-1H-tetrazole in
acetonitrile to the next phosphoramidite base to form the activated phosphorous; the free
hydroxyl group on the support binds to the activated phosphorous to form the unstable
phosphite linkages between the two bases. This coupling takes about 6 min for all ultramild
protected 2’-OMe phosphoramidite bases and 10 min for 5’-thiol modifier amidite. The
column was then washed with acetonitrile to remove any remaining 5-ethylthio-1H-
tetrazole, unreacted base phosphoramidite and by-products. The unstable phosphite linkage
was stabilized with a solution of sulfurizing reagent (such as Beaucage reagent) to form the
more stable thiophosphate linkage (for phosphorothioates). Remaining unreacted active free
hydroxyl group on the solid support (typically less than 2%) was capped to prevent the
formation of failure sequences. In the case of regular 2’-OMe-C solid supports, standard
acetic anhydride and N-methyl-imidazole solution were used as capping reagents. However,
when Tamra fluorophore solid supports and ultramild protected all 2’-O-methyl
phosphoramidite bases were used, 5% phenoxyacetic anhydride in tetrahydrofuran/pyridine
and 16% N-methyl-imidazole in tetrahydrofuran were used for capping. Then the steps were
repeated until the desired length of oligonucleotide sequence has been assembled onto the
solid supports. A 5’-thiol linker was introduced at the end of the oligonucleotide synthesis.
Normally we obtained a coupling efficiency of 98-100% at each cycle.
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After oligonucleotides were synthesized, they were first treated with 10% diethylamine in
acetonitrile for 5 min × 2 followed by acetonitrile wash to remove the 2-cyanoethyl group
from the phosphate backbone and prevent the elimination of 3’-Tamra fluorophore from the
oligonucleotide chain. The oligonucleotides were then reacted with 2 mL of deprotection
solution (tert-butylamine: methanol: water = 1:1:2, v/v) per micromole of the oligo bound
solid support for 8h at 55 °C. After cooling to room temperature, the supports were filtered
off and washed with HPLC grade of water. The combined filtrate was immediately
evaporated to dryness. The crude mass was re-suspended in 0.1M TEAA buffer and purified
by reverse-phase HPLC using a Zorbax C18 column to obtain 623 SSO disulfide. The
structure of the disulfide oligo was confirmed by MALDI-TOF mass spectroscopy.
Bivalent cyclic RGD peptides were synthesized by conventional means and characterized by
MALDI-TOF mass spectrometry 50. Peptides of this type have been extensively used in
imaging studies 51,52. In this case a maleimide moiety was inserted into the peptide to allow
facile conjugation with a thiol group on the 5’ end of the oligonucleotide.
Conjugation of bivalent cRGD peptide to 623 SSO
Conjugation of cRGD peptide to anionic phosphorothioate oligonucleotides is a two-step
chemical process as shown in Scheme 1 for the SSO termed 623. It involves generation of a
thiol group (-SH) from a disulfide oligonucleotide and reaction of the thiol oligonucleotide
to a maleimide bearing bivalent cRGD peptide via Michael addition. Briefly, the disulfide
bond of the Tamra-623-disulfide SSO was reduced with 100 mM of aqueous DTT solution
at room temperature followed by a Sep-PAK C18 cartridge purification (step I of Scheme 1).
Any residual amount of DTT was removed by washing with 5% acetonitrile in a 0.1M
TEAA buffer. Thiol oligonucleotide (Tamra-623-SH) was eluted from the Sep-PAK
cartridge with 50% aqueous acetonitrile. The eluted thiol oligonucleotides were directly
used for the conjugation reaction. When the two species were mixed together in a solution of
salt and acetonitrile (400mM KCl, 40% aq. acetonitrile), the reaction was completed within
3h at room temperature (step II of Scheme 1). The progress of the conjugation reaction was
monitored by anion exchange HPLC using a pre-pack Resource Q column (1 mL) in 50% of
formamide in Tris-chloride buffer. All thiol (>95%) oligonucleotides were shifted to
conjugates with bicyclic RGD peptide. We have used 3 equivalents of peptides relative to
thiol oligonucleotides in the conjugation step. No aggregation was observed in the reaction
mixture. After purification using a Resource Q column, the conjugates were desalted over
milli-Q water using slide-A-lyser desalting cassette. The conjugate appeared as a clear
solution in water after desalting. After lyophilization, the conjugate was re-suspended in
sterile water at a concentration of 50-100 μM for long-term storage. All structures of
RGD-623 SSO conjugates were confirmed by MALDI-TOF mass spectroscopy. The
chemical structure of the cRGD-623-Tamra conjugate is shown in Figure 1.
Conjugation of Bombesin (6-14) peptide to 623 SSO
The preparation of bombesin-SSO conjugates 53 was very similar to that used for the cRGD
conjugates. The same disulfide version of Tamra-623-SSO as shown in Scheme 1 was used.
The chemical structure and synthetic route for bombesin-623-Tamra conjugate is shown in
Figure 2. About 5 equivalent of maleimide-bombesin peptide was consumed relative to the
thiol oligonucleotide to convert all starting oligo into its conjugated product. The conjugates
were analyzed and purified by reverse-phase HPLC method using an XTerra C18 column on
a Varian system. The thiol oligos and their bombesin conjugates were clearly separated by
the RP-HPLC method. The conjugates were eluted later than thiol oligonucleotide by RP-
HPLC analysis and were very soluble in metal free sterile water after lyophilization.
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Conjugation of multivalent cRGD peptides to siRNA
The synthetic route for the chemical conjugation of bi-, tri- and tetravalent cyclic RGD
peptides to a firefly luciferase siRNA was extensively discussed in a recent publication 54.
Very briefly, a reactive cysteine thiol group (-SH) was introduced into the peptide sequence
to allow chemical conjugation with a maleimide functionality of the 3’-sense strand of
luciferase siRNA via Michael addition reaction. In other words the opposite strategy was
followed as compared to the SSO conjugates. This was necessary to maintain the 5’ position
of the antisense strand of the siRNA in an unmodified state. About 2.5 equivalents of
reactive thiol bearing peptides were used relative to the maleimide sense strand
oligonucleotide. All starting sense strands were consumed and converted to the cRGD
conjugated sense strand. None of the conjugates precipitated in the reaction mixture
containing 400mM KCl and 40% aq. acetonitrile. After 5-fold of dilution with HPLC grade
of water, the crude conjugates were purified by reverse-phase HPLC using an XTerra RP-18
column attached to an AKTA purifier and isolated with an excellent yield (conjugates:
bivalent 95%, trivalent 84%, tetravalent 67%). No noticeable aggregation was seen when re-
suspended in sterile water after lyophilization. For all cases, the structure of the final
conjugate was confirmed by LC-MS analysis. To obtain the desired cRGD-siRNA
conjugates, the partner antisense strand was annealed with the cRGD conjugated sense
strand in sterile water at elevated temperature for 3 min followed by slow cooling.
BIOLOGICAL ACTIONS OF PEPTIDE OLIGONUCLEOTIDE CONJUGATES
In order to examine the specificity of the peptide-oligonucleotide conjugates for membrane
receptors, we tested cellular uptake of the conjugates in the tumor cells over-expressing
these receptors. Thus, we used integrin αvβ3-expressing A375 melanoma cells 39 and M21+
cells 54 to test the cellular uptake of cRGD-oligonucleotide conjugates, and bombesin
(BBN) receptor-expressing PC3 cells to test intracellular delivery of BBN-SSO
conjugates 53. In all these cases, peptide-oligonucleotide conjugates showed significantly
higher uptake than that of the “free” oligonucleotides, and this increase was reversed by an
excess amount of free peptide, confirming receptor specific cellular delivery39,53,54.
Enhancement of cellular uptake by peptide conjugation depends on the binding affinity of
the peptides to their receptors and the density of the receptors on the cell surface 55. On the
other hand, the intrinsic uptake rate of the oligonucleotides also plays a role. “Free”
phosphorothioate (PS) oligonucleotides can bind to membrane proteins and enter cells via
endocytosis 56, and their cellular uptake is more efficient than “free” siRNA
oligonucleotides. Therefore, RGD-siRNA showed about 20-fold higher uptake than “free”
siRNA, while RGD-SSO, in which SSO is a PS oligonucleotide, only showed about 2-fold
higher uptake than free SSO 39.
Although the enhancement in cellular uptake of RGD-SSO was modest, the functional
activity caused by the RGD-SSO conjugate was disproportionately higher than that of “free”
SSO 39. The functional delivery was tested in receptor-expressing cells stably transfected
with a luciferase gene interrupted by an abnormally spliced intron. Thus, intranuclear
delivery of the SSO corrects splicing and allows positive readout of luciferase expression in
these cells. At the concentration of 150 nM, RGD-SSO showed about 6-fold higher
induction than the SSO in A375 cells 39. Similarly, in BBN receptor-expressing PC3 cells,
BBN-SSO showed 2-fold higher cellular uptake, but about 5-fold higher induction than
“free” SSO 53. The disconnection between cellular uptake and functional activity was also
observed for RGD-siRNA conjugates. In this study, luciferase siRNA was linked with bi-,
tri-, and tetravalent cRGD peptides, and their cellular uptake and RNAi activity were then
examined using luciferase-expressing and integrin αvβ3 positive M21(+) human melanoma
cells 54. The bi-, tri-, and tetravalent cRGD conjugates were taken up by M21(+) cells to
approximately the same degree However, only the tri- and tetravalent versions produced
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RNAi activity, while the bivalent version had little effect 54. One cause of this discord may
be the distinct internalization pathways that the peptide-oligonucleotide conjugates
undertake. We did a follow-up study to resolve endocytosis pathways of RGD-SSO 57.
Using endocytosis inhibitors and a dominant-negative form of dynamin GTPase, we have
identified an actin-dependent, dynamin-dependent pathway for uptake of the RGD-SSO
conjugate in A375 cells, and an unusual actin-independent, dynamin-independent pathway
for uptake of the unconjugated PS oligonucleotide, suggesting that the route of
internalization could affect the magnitude of the biological response 57.
The distinct endocytotic process may also cause distinct kinetics of pharmacological action
of the peptide-oligonucleotide conjugates. Both RGD-SSO and BBN-SSO conjugates
produced a gradual increase followed by a gradual decline in reporter induction, while a
cationic lipid-SSO complex caused a rapid increase followed by a monotonic decline 39,53.
The peptide-oligonucleotide conjugates need to be transported through multiple endosomal
compartments before export from the endosomes, and the release may be slow, as the
current conjugate system does not include an endosomal release entity. In order to further
enhance the functional activity of the conjugates, the RGD-SSO conjugate was formulated
into polyplexes with a cationic polymer, polyethylenimine, which is able to cause
endosomal release via the proton sponge effect 58. The resultant polyplexes of RGD-SSO
conjugate demonstrated dramatic increases in the pharmacological response of splicing
correction compared to free RGD-SSO conjugate or the polyplexes of unconjugated SSO,
presumably through integrin-mediated endocytosis and rapid endosomal release 58. This
provides a novel method to construct multifunctional nanoparticle-based delivery systems
using peptide-oligonucleotide conjugates.
CONJUGATION OF SMALL MOLECULES
As mentioned above, small molecule ligands with high affinity to specific cell surface
receptors provide an interesting opportunity for the design of oligonucleotide conjugates.
However, there are several caveats involved. First, it is important to understand that much of
the structure of the small molecule will be involved in the interaction with its receptor. This
limits ones’ ability to introduce chemical modifications that allow conjugation to the
oligonucleotide. Second, the presence of the large, highly charged oligonucleotide strand
can affect the affinity of binding between the small molecule ligand and its receptor. This
latter effect can potentially be ameliorated by introducing an uncharged linker between the
oligonucleotide and the ligand. Another consideration is that many of the small molecule
ligands developed by the pharmaceutical industry are relatively lipophilic since they are
designed for oral administration 59. Lipophilicity can create two types of problems. First, the
solubility of the conjugate can be reduced, especially when several ligands are linked to a
single oligonucleotide. Second, the presence of lipophilic moieties can lead to non-specific
binding to cell membranes; once again this is particularly true when several small molecule
ligands are attached.
Our laboratory has had both successful and less than successful experiences with small
molecule oligonucleotide conjugates. On the positive side, as mentioned above, we prepared
mono-and trivalent conjugates between a SSO and anisamide, a ligand for the sigma
receptor 45. Importantly, anisamide had previously been conjugated to liposomes for
targeting purposes 60 and thus something was known about how to conjugate the molecule
without loss of receptor binding activity. In our study we somewhat modified the coupling
approach and then developed a solid phase synthesis of the final ligand-oligonucleotide
conjugate. Thus, we synthesized a phosphoramidite version of anisamide that could
incorporated using a standard DNA synthesizer as depicted in Scheme 2. The anisamide
conjugates, especially the trivalent version, were more effective than an unconjugated SSO
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in inducing splice correction in a reporter gene stably transfected into human prostate tumor
cells. The process seemed to be at least somewhat receptor specific since co-incubation of
the cells with haloperidol, a sigma receptor antagonist, partially blocked cellular uptake of
the anisamide-SSO conjugates.
We attempted to extend these results to another ligand-receptor system but with less
favorable results. DREADDs are G Protein Coupled Receptors (GPCRs) that have been
genetically engineered to respond to a unique test ligand rather than to endogenous
ligands 61. In this case we used a DREADD that was based on the M3 muscarinic receptor
but that responded to clozapine or clozapine-N-oxide (CNO) rather than acetylcholine its
normal ligand. Since the M3 receptor and its corresponding DREADD are coupled to Gq/11
G-Proteins, the functional assay for testing potency of ligands in this system is modulation
of intracellular calcium levels, which is easily determined via a fluorescent dye assay. Based
on structure activity studies of clozapine derivatives in the DREADD system, analogs of
clozapine and CNO were synthesized that had a hydroxyl connected via a linker to one of
the two nitrogens on the seven-member clozapine ring (Scheme 3). These compounds
maintained good potency in the calcium modulation assay (51 nM for the clozapine analog).
They were subsequently reacted with 1,1’-carbonyldiimidazole and the product of this
reaction was then conjugated to a SSO having a 5’-aminolinker; both mono-and trivalent
versions were produced.
We then examined the biological activities of these molecules with disappointing results
(unpublished observations). For example, using the calcium modulation assay we found that
the potency of the conjugates were sharply reduced; thus the monomeric and trimeric
clozapine analog-SSO conjugates had ED50s of approximately 1 uM and 0.1uM as
compared to approximately 1 nM for clozapine itself. Despite the use of a six-carbon
aminolinker, the presence of the charged oligonucleotide seemed to reduce the affinity of the
ligand for its receptor. Studies of the cellular uptake of the conjugates were even more
disappointing. We used a cell line that had been stably transfected so as to over-express the
M3 DREADD. Initially we were pleased to find that the clozapine and CNO analog SSO
conjugates displayed substantially higher cellular uptake than the unconjugated parent SSO.
However, we then compared uptake in cell lines that did or did not express the DREADD
and found little difference. Clozapine and its relatives are quite lipophilic as they must be
since they are used to treat disease of the central nervous system; thus the XLogP3 for
clozapine is 3.2 (PubChem). We suspect that the rather high lipophilicity of the clozapine
analogs caused non-specific binding of the conjugates to cell membranes that overwhelmed
the relatively poor specific binding to the receptor. It is interesting to note that anisamide is
substantially less lipophilic than clozapine having a XLogP3 of 0.8 which may account for
its better success as a ligand for oligonucleotide conjugation.
CONCLUSIONS
In summary, it is possible to synthesize a variety of ligand-oligonucleotide conjugates by
relatively simple means. In those cases where the ligand binds selectively to a specific cell
surface receptor, the conjugates have often shown receptor-dependent, cell type specific
uptake and enhanced biological effects. However, important issues remain to be solved. For
example, even after receptor dependent uptake, much of the oligonucleotide remains
sequestered in pharmacologically inert endosomal compartments. Combining targeted
ligand-oligonucleotide conjugates with means to promote endosome escape will be a
challenge for the future. We have recently made some progress on this aspect by using a
small molecule to enhance escape of anionic antisense and splice switching oligonucleotides
from a subset of endosomes resulting in enhanced pharmacological effect 62. A special
situation prevails in the case of conjugates involving small molecules. Unlike the situation
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with peptides or carbohydrates, it is more challenging to link the small molecule ligand to
the oligonucleotide in a manner that will preserve specific, high affinity ligand-receptor
binding. Despite these concerns, however, it seems likely that ligand-oligonucleotide
conjugates will be an important aspect of the future development of oligonucleotides as
therapeutic agents.
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Figure 1. Structure of a bivalent cyclic RGD-oligonucleotide conjugate
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Figure 2. Synthesis and structure of a bombesin-oligonucleotide conjugate
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Scheme 1. Conjugation of cRGD peptides with a thiol modified 2’-O-Me phosphorothioate
oligonucleotide
The 5’ disulfide splice switching oligonucleotide is reduced and then conjugated to a
maleimide terminated cyclic RGD peptide, as described in the text.
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Scheme 2. Preparation of anisamide-oligonucleotide conjugates (reproduced with permission
from reference 45)
N-[2-(2-hydroxyethoxy)ethyl]-4-methoxybenzamide, a derivative of anisamide with a
reactive hydroxyl group (1) is converted to a phosphoramidite (2). Solid phase DNA
synthesis is used to prepare monovalent (3) or trivalent (4) anisamide-oligonucleotide
conjugates.
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Scheme 3. Preparation of clozapine-oligonucleotide conjugates
A clozapine derivative with a reactive hydroxyl group (1) was reacted with 1,1’ -
carbonyldiimidazole (2) and the product (3) was conjugated to mono- or tri-branched
oligonucleotides (4,5) that contained 5’-aminolinkers to produce mono- or trimeric
clozapine-oligonucleotide conjugates (6.7).
Alam et al. Page 16
Bioorg Med Chem. Author manuscript; available in PMC 2014 October 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
